Iovance Biotherapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Iovance Biotherapeutics Inc 's ROA in the second quarter of 2026?
Iovance Biotherapeutics Inc recorded a cumulative net loss of $-290 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -31.65%.

However, within the Healthcare sector 434 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3772, from total ROA ranking in the first quarter of 2026 at 4490.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	0.89 %	-4.25 %	6.74 %	-2.35 %	1.22 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-290	-354	-391	-398	-390
Return On Assets (TTM)	-31.65 %	-38.77 %	-42.36 %	-43.76 %	-42.66 %
IOVA's Total Ranking	# 3772	# 4490	# 3945	# 3964	# 4010
Total Assets (TTM) in million	916	926	913	905	907
Seq. Total Assets Change	-1.09 %	1.37 %	0.91 %	-0.27 %	-6.13 %
Seq. Net Income Change	-	-	-	-	-

IOVA's 5 Years Annual ROA >> Back to IOVA Management Effectiveness >> Compare IOVA ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 47
Sector	# 435
Overall	# 3637

Return On Assets Statistics
High	Average	Low
3731.77 %	-220.24 %	-6596.67 %
(Mar 31 2013)		(Dec 31 2012)

Financial Statements
Iovance Biotherapeutics Inc 's Assets	$ 916 million	IOVA's Balance sheet
Iovance Biotherapeutics Inc 's Income	$ -47 million	Quarterly IOVA's Income Statement
IOVA's Income by Division		See IOVA's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	6.74 %	18.96 %	21.82 %	-17.03 %	-0.39 %
Total Assets in million	913	855	719	590	711
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-391	-372	-444	-396	-342
Annual Return On Assets	-42.82 %	-43.5 %	-61.75 %	-67.06 %	-48.1 %

IOVA's 5 Years Annual ROA >> Back to IOVA Management Effectiveness >> Compare IOVA ROA to its Competitors

More Return On Assets Ratios
IOVA's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
IOVA's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for IOVA's Competitors
Subscribers only: Roa for Iovance Biotherapeutics Inc 's Suppliers
Subscribers only: Return On Assets for IOVA's Customers

You may also want to know
IOVA's Roi	IOVA's Inventory Turnover Ratio	IOVA's Growth Rates	IOVA's Dividend Comparisons
	IOVA's Profitability Ratios	IOVA's Asset Turnover Ratio	IOVA's Dividend Growth
IOVA's Roe	IOVA's Valuation Ratios	IOVA's Financial Strength Ratios	IOVA's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T13:52:15+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.